Guidelines & Consensus
IPMN beyond the cyst: toward a broader framework of pancreatic and systemic cancer susceptibility
Okabayashi et alExpert Review of Gastroenterology & Hepatology
While clinical guidelines for intraductal papillary mucinous neoplasms (IPMNs) have traditionally concentrated on cyst morphology to gauge progression to pancreatic ductal adenocarcinoma (PDAC), IPMN may also signal wider pancreatic and systemic oncologic susceptibility. In the pancreas, field cancerization can manifest as concomitant and metachronous PDACs that emerge independently of the index IPMN lesion.
Beyond the pancreas, IPMNs have been linked to an elevated risk of extrapancreatic malignancies, particularly colorectal, gastric, and breast cancers. Clinical interpretation of these associations must account for surveillance bias, advanced age, shared environmental exposures, and underlying hereditary susceptibility. In particular, germline pathogenic variants in BRCA1, BRCA2, PALB2, and ATM highlight a subset of patients who may benefit from risk-adapted genetic testing and broader surveillance protocols.
Emerging diagnostic modalities—such as liquid biopsies, radiomics, artificial intelligence, and multi-omics profiling—offer potential pathways toward individualized risk stratification. However, current evidence linking IPMNs to systemic cancer susceptibility is largely observational and does not establish causality. Conventional morphological surveillance should be supplemented with patient-centered risk assessments, while advanced molecular and imaging tools require formal prospective validation before routine implementation.
Key Takeaways
- Pancreatic ductal adenocarcinoma can develop concomitantly or metachronously independent of the index IPMN via pancreatic field cancerization, with reported associations extending to extrapancreatic colorectal, gastric, and breast malignancies.
- Identification of IPMN supports risk-adapted genetic assessment for germline pathogenic variants, specifically including BRCA1/2, PALB2, and ATM.
- Evidence linking IPMN to broader cancer susceptibility remains observational and non-causal, requiring prospective validation of emerging biomarkers, radiomics, and artificial intelligence before routine clinical integration.
Read the original sourceExpert Review of Gastroenterology & Hepatology
